The U.S. Food and Drug Administration has approved Genentech's Tecentriq in combination with lurbinectedin for maintenance treatment of adult patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE